Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Genmab","sponsor":"Tavotek Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genmab"},{"company":"ISD Immunotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ISD Immunotech Granted US and EU Patents for Novel Severe Systemic Lupus Erythematosus (SLE) Therapy Candidate ISD017","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Peptide","graph2":"ISD Immunotech"}]

ISD Immunotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ISD Immunotech Granted US and EU Patents for Novel Severe Systemic Lupus Erythematosus (SLE) Therapy Candidate ISD017

Details:

US patent covering the lead candidate ISD017, which uniquely blocks all aspects of STING pathway overactivation in severe systemic lupus erythematosus (SLE) patients.

Lead Product(s): ISD017

Therapeutic Area: Immunology Product Name: ISD017

Highest Development Status: Undisclosed Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2021

ASK
US

Upload
your Pipeline Activity

Genmab

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tavotek Inks Research Pact with Genmab to Develop Bispecific Antibodies using Duobody Technology Platform

Details:

The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.

Lead Product(s): Bispecific antibodies

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Tavotek Biotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 25, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY